Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine of clarithromycin effect on developing of bronchopulmonary dysplasia in preterm babies.
The investigators planned that clarithromycin treatment in preterm babies who are under 1250 grams birth weight.
The investigators aimed with this treatment, the bronchopulmonary dysplasia rate of preterm babies may decrease.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clarithromycin | Active Comparator | Fist group treated with clarithromycin which is include 10 days application. |
|
| placebo | Placebo Comparator | Second group treated with salin as same as amount of clarithromycine volume |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia | Drug |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Bronchopulmonary dysplasia | On the 28. day of birth, The investigator will determine the baby whether has developed bronchopulmonary dysplasia | 28. day of birth |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | During to hospitalisation the investigator will determine and record some co-morbidities of BPD such as intracranial hemorrhage, necrotizing enterocolitis, patent ductus arteriosus rates.From date of randomization until the end of the hospitalisation up to the 3 months of life. | Participants will be followed for the duration of hospital stay, an expected average of postnatal 40 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sadık Yurttutan, M.D | Contact | 0905059079727 | sdkyurttutan@gmail.com | |
| Fuat Emre Canpolat, M.D. | Contact | femrecan@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ugur Dilmen, Prof. Dr. | Zekai Tahir Burak Women's Health Research and Education Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zekai Tahir Burak Maternity Teaching Hospital | Recruiting | Ankara | Middle Anatolia | 06600 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
| Saline |
| Drug |
|
| ID | Term |
|---|---|
| D001997 | Bronchopulmonary Dysplasia |
| ID | Term |
|---|---|
| D055397 | Ventilator-Induced Lung Injury |
| D055370 | Lung Injury |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007235 | Infant, Premature, Diseases |
| D007232 | Infant, Newborn, Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided